Shots: The approval is based on P-III BEACON CRC trial evaluating Braftovi (300mg, qd) + Erbitux vs irinotecan + Erbitux or Folfiri + Erbitux in a ratio (1:1:1) in 441 […]readmore
Tags : Metastatic Colorectal Cancer
In an interview with PharmaShots, Mark Erlander, CEO of Cardiff Oncology shared his views on the data presented at the ASCO-GI Conference, P-Ib results of Onvansertib, what these results meant […]readmore
Clinical Trials
Pharma
Chi-Med Initiates P-III FRESCO-2 Study of Fruquintinib in Metastatic Colorectal
Shots: The P-III FRESCO-2 study involves assessing of fruquintinib vs PBO in patients with m-CRC in ~130 sites across 10 countries The company has initiated the study in the US, […]readmore
Shots: The NMPA has approved Byvasda for the treatment of patients with NSCLC and metastatic colorectal cancer. The approval follows TYVYT (sintilimab injection) approval, indicated to treat patients with Hodgkin’s […]readmore
Biosimilars
Clinical Trials
Regulatory
Henlius Reports Positive Results of HLX04 (biosimilar, bevacizumab) in P-III
Shots: HLX04 is a biosimilar that binds to vascular endothelial growth factor (VEGF) for inhibiting angiogenesis where VEGF acts for promoting growth of blood vessels can inhibit tumor angiogenesis further […]readmore
Shots: The two companies divulged the results of ongoing P-II DESTINY-CRC01 study assessing Enhertu in patients with HER2+ unresectable and/or m-colorectal cancer, prior treated with 2L standard therapies. Results: ORR […]readmore
Shots: QIAGEN launches its therascreen BRAF V600E RGQ PCR Kit as a CDx to Pfizer’s Braftovi (encorafenib) in combination with Lilly’s Erbitux (cetuximab) for the treatment of patients with m-CRC […]readmore
Shots: The focus of the study is to evaluate the safety & tolerability of the combination therapy in addition to ORR as well as immunological and histologic readouts from tumor […]readmore
Shots: Bayer, BMS and Ono collaborate to evaluate the combination of Bayer’s Stivarga (regorafenib) with BMS & Ono’s Opdivo (nivolumab) vs regorafenib in patients with micro-satellite stable mCRC The collaboration […]readmore